Randomized Phase II Stereotactic Ablative Radiation Therapy for Metastatic Unresected Renal Cell Carcinoma Receiving Immunotherapy (SAMURAI)

Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected RCC Receiving Immunotherapy (SAMURAI)

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Condition: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Study ID: NCT05327686

Conference Coverage

Conference Highlights Written by Physician-Scientist

ASCO 2023: NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Patients with Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Presented by Rana McKay, MD

(UroToday.com) The 2023 American Society of Clinical Oncology (ASCO) annual meeting held in Chicago, IL between June 2^nd and June 6^th was host to a kidney and bladder cancers poster session. Dr. Rana McKay presented the rationale and study framework for SAMURAI, a randomized phase II trial evaluating stereotactic ablative radiation therapy (SABR) for patients with metastatic, unresected renal cell carcinoma (RCC) receiving systemic immunotherapy. Read More

Trials in Progress

Randomized Phase II Stereotactic Ablative Radiation Therapy for Metastatic Unresected Renal Cell Carcinoma Receiving Immunotherapy (SAMURAI)

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Login